百诚医药：与众神创新签署BIOS-0629项目技术开发合作协议

Core Viewpoint - The company has entered into an exclusive collaboration agreement with Zhongshen Innovation for the development of the innovative drug BIOS-0629 in the Greater China region, which includes mainland China and Hong Kong, Macau, and Taiwan [1] Group 1 - The collaboration includes a technical development cooperation agreement and a supplementary agreement [1] - Zhongshen Innovation will pay milestone payments of 300 million yuan based on research and development milestones [1] - Upon the product's launch in the Greater China region, the company will receive a 10% commission on sales revenue [1]